--- title: "Rhythm Pharmaceuticals is likely to exceed US$750 million in rare-obesity drug sales in 2027, more than double the annual sales pace implied by its third-quarter 2026 results." description: "On 3 November LG Chem disclosed a revised licence for its experimental oral obesity drug, with Rhythm agreeing to an extra US$350 million in fixed payments in exchange for lower future royalties acros" url: "https://bilby.ai/predictions/p/203/rhythm-pharmaceuticals-is-likely-to-exceed-us-750-million-in-rare-obesity-drug-s" markdown: "https://bilby.ai/predictions/p/203/rhythm-pharmaceuticals-is-likely-to-exceed-us-750-million-in-rare-obesity-drug-s.md" index: "https://bilby.ai/llms.txt" --- > For agents: Bilby answers questions about what governments do, from documents collected at source and checked by research analysts. To ask Bilby yourself, connect to its MCP server at https://pulse.bilby.ai/mcp (setup: https://docs.bilby.ai/developers/mcp-server). Every page on this site is also markdown: add .md to its address, or send Accept: text/markdown. https://bilby.ai/llms.txt lists them all. # Rhythm Pharmaceuticals is likely to exceed US$750 million in rare-obesity drug sales in 2027, more than double the annual sales pace implied by its third-quarter 2026 results. - **Made:** 4 Nov 2026 - **By:** Owen Bae - **Market:** South Korea - **First reported by:** Herald Economy - **Outcome:** Unresolved On 3 November LG Chem disclosed a revised licence for its experimental oral obesity drug, with Rhythm agreeing to an extra US$350 million in fixed payments in exchange for lower future royalties across its obesity-drug portfolio. The accompanying US$500 million committed loan facility should help cover those payments and clinical trials while protecting spending on finding patients and securing insurance cover. Rhythm can expand sales of its existing medicine Imcivree without waiting for the oral drug to win approval. Imcivree launched in Japan in October and European launches are planned from 2027. The number of patients on paid treatment worldwide rose 20% in the third quarter, while US doctors had submitted more than 700 treatment requests by September’s end. Japan’s initial prescription limits and European reimbursement negotiations could slow progress, so growth will depend on getting eligible patients onto regular paid treatment. First reported by [Herald Economy](https://biz.heraldcorp.com/article/10923977?sec=029) ![Causal flowchart for Rhythm Pharmaceuticals’ rare-obesity drug sales](https://cms.bilby.ai/api/media/file/adt-2026-11-04-prediction-203.png?prefix=cms-media) [Ask Bilby about this prediction](https://pulse.bilby.ai/?prompt=Rhythm%20Pharmaceuticals%20is%20likely%20to%20exceed%20US%24750%20million%20in%20rare-obesity%20drug%20sales%20in%202027%2C%20more%20than%20double%20the%20annual%20sales%20pace%20implied%20by%20its%20third-quarter%202026%20results.) ## Ask Bilby about it Carry the prediction into a question: what has changed since, who decides, and who is exposed. - [What has changed since it was made?](https://pulse.bilby.ai/?prompt=What%20has%20changed%20since%20Bilby%20predicted%20this%3F%20Rhythm%20Pharmaceuticals%20is%20likely%20to%20exceed%20US%24750%20million%20in%20rare-obesity%20drug%20sales%20in%202027%2C%20more%20than%20double%20the%20annual%20sales%20pace%20implied%20by%20its%20third-quarter%202026%20results.) - [Who decides whether it happens?](https://pulse.bilby.ai/?prompt=Who%20decides%20whether%20this%20happens%3F%20Rhythm%20Pharmaceuticals%20is%20likely%20to%20exceed%20US%24750%20million%20in%20rare-obesity%20drug%20sales%20in%202027%2C%20more%20than%20double%20the%20annual%20sales%20pace%20implied%20by%20its%20third-quarter%202026%20results.) - [Who gains and who loses if it does?](https://pulse.bilby.ai/?prompt=Who%20gains%20and%20who%20loses%20if%20this%20happens%3F%20Rhythm%20Pharmaceuticals%20is%20likely%20to%20exceed%20US%24750%20million%20in%20rare-obesity%20drug%20sales%20in%202027%2C%20more%20than%20double%20the%20annual%20sales%20pace%20implied%20by%20its%20third-quarter%202026%20results.) ## More from South Korea 27 predictions on South Korea so far, newest first. - 27 Oct 2026 · [Washington’s South Korean advanced memory chipmaker anti-China restrictions will hit Samsung much harder than Beijing.](https://bilby.ai/predictions/p/188/washington-s-south-korean-advanced-memory-chipmaker-anti-china-restrictions-will) · Unresolved - 26 Oct 2026 · [South Korea’s steel market pushes back on China yet harder.](https://bilby.ai/predictions/p/187/south-korea-s-steel-market-pushes-back-on-china-yet-harder) · Unresolved - 21 Oct 2026 · [Samsung Electronics will secure at least KRW 1 trillion (US$700 million) in state-backed supplier loan guarantees by 30 June 2027.](https://bilby.ai/predictions/p/176/samsung-electronics-will-secure-at-least-krw-1-trillion-us-700-million-in-state-) · Unresolved [All 27 from South Korea](https://bilby.ai/predictions/log?tag=south-korea) · Marked true or false when each resolves ## See what we’re seeing next. New predictions in the Asia Daily Take, free every weekday, and in Bilby whenever you have a question. [Get the Asia Daily Take](https://bilby.ai/asia#asia-daily-take) · [Try Bilby](https://pulse.bilby.ai/sign-up)